EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access

The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes

Luís Mendonça iD, Henrique Moura iD, Paulo Castro Chaves iD, João Sérgio Neves iD, João Pedro Ferreira iD

Clinical Journal of the American Society of Nephrology · 2025-02 · 20 (2) · 159-168

DOI: 10.2215/cjn.0000000584 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 08.10.2024. Verfasst von Luís Mendonça und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Cardiovascular Research and Development - Unic@RISE, Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto,…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Hypoglycemic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points This is an updated meta-analysis about glucagon-like peptide-1 receptor agonists (GLP-1 RAs) incorporating findings from the recently published FLOW and SELECT studies. Our findings show that GLP-1 RAs reduce kidney disease progression in patients with type 2 diabetes or overweight/obesity status, with or without CKD. Our meta-analysis supports the use of GLP-1 RAs for reducing the risk of adverse kidney outcomes across different populations.

Background

Recent data indicate a potential benefit of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on the progression of kidney disease among patients with CKD. Our aim was to evaluate the effect of GLP-1 RAs on the risk of worsening kidney function across different populations.

Methods

We conducted a meta-analysis of randomized controlled trials that tested GLP-1 RA treatment versus placebo in individuals with type 2 diabetes or with overweight/obesity status, with or without CKD, with kidney events reported as primary or secondary end points. The primary outcome was the occurrence of worsening kidney function, defined as either a doubling of serum creatinine or a ≥40% or ≥50% decline in eGFR, according to each study report. Secondary outcomes included development of persistent macroalbuminuria and a composite of worsening kidney function or the development of persistent macroalbuminuria. Subgroup analyses were performed by eGFR and albuminuria categories. The results are presented as risk ratios with 95% confidence intervals.

Results

Eight trials were eligible, including a total of 68,572 patients, of whom 34,042 (49.6%) received GLP-1 RA treatment. During follow-up, 1028 participants receiving GLP-1 RA (3.0%) and 1150 participants receiving placebo (3.5%) experienced worsening kidney function. Treatment with GLP-1 RAs (versus placebo) resulted in a reduction in the risk of worsening kidney function (risk ratios, 0.84; 95% confidence interval, 0.77 to 0.91; P < 0.001). In addition, treatment with GLP-1 RAs significantly reduced the risk of developing persistent macroalbuminuria and the risk of the composite outcome of worsening kidney function or development of persistent macroalbuminuria. The results were consistent in patients with and without CKD.

Conclusions

In conclusion, our meta-analysis suggests that GLP-1 RA reduce kidney disease progression in type 2 diabetes or overweight/obesity regardless of CKD status. Podcast This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2025_02_14_CJASNFeb20.2.2142025.mp3

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Renal Insufficiency, ChronicHypoglycemic AgentsDiabetic NephropathiesKidneyHumansRandomized Controlled Trials as TopicObesityDisease ProgressionTreatment OutcomeOverweight

Stichwörter der Autor:innen

GFRalbuminuriadiabetes mellitusobesity

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Unit of Cardiovascular Research and Development - Unic@RISE, Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal.
  • Department of Nephrology, ULS São João, Porto, Portugal.
  • Department of Medicine, ULS São João, Porto, Portugal.
  • Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal.
  • Centre d'Investigations Cliniques Plurithématique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

ORCID-Profile: Luís Mendonça, Henrique Moura, Paulo Castro Chaves, João Sérgio Neves, João Pedro Ferreira

Zitieren

APA

Mendonça, L., Moura, H., Chaves, P. C., Neves, J. S., & Ferreira, J. P. (2025). The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes. Clinical Journal of the American Society of Nephrology, 20(2), 159-168. https://doi.org/10.2215/cjn.0000000584

Vancouver

Mendonça L, Moura H, Chaves PC, Neves JS, Ferreira JP. The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes. Clinical Journal of the American Society of Nephrology. 2025;20(2):159-168. doi:10.2215/cjn.0000000584

BibTeX
@article{Mendona2025,
  author = {Mendonça, Luís and Moura, Henrique and Chaves, Paulo Castro and Neves, João Sérgio and Ferreira, João Pedro},
  title = {The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2025},
  volume = {20},
  number = {2},
  pages = {159--168},
  doi = {10.2215/cjn.0000000584}
}
Kostenlos starten →